BMS joins forces with Adaptive Biotechnologies on cancer biomarkers
SEATTLE—A collaboration agreement was struck in early May between Adaptive Biotechnologies Corp. and Bristol-Myers Squibb Co. with the purpose of discovering immunological biomarkers in oncology. Per the terms of the agreement, Adaptive Biotechnologies will use immunoSEQ, its proprietary immune profiling assay, to identify potential biomarkers that could inform drug response. Financial information for the agreement was not disclosed.
"We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents," Chad Robins, CEO and founder of Adaptive Biotechnologies, said in a press release. "Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves."